Back to top
more

Cytokinetics (CYTK)

(Delayed Data from NSDQ)

$65.57 USD

65.57
1,283,835

-0.35 (-0.53%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $65.55 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CYTK

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cytokinetics, Incorporated [CYTK]

Reports for Purchase

Showing records 81 - 100 ( 304 total )

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 81

03/30/2020

Daily Note

Pages: 94

Market Shudders But We See Names to Outperform.

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 82

03/04/2020

Company Report

Pages: 8

Our Investment Case Is Clear: We Are All in

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 83

02/26/2020

Company Report

Pages: 7

Omecamtiv Endgame Now Set; Project Positive Outcome to Be Good for Heart Failure Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 84

02/07/2020

Company Report

Pages: 10

HCM KOL Dinner Takeaways; Excitement Ahead in a Challenging Space

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 85

01/17/2020

Company Report

Pages: 7

Omecamtiv Endgame Not Too Far off Now; Expect Significant Boost in CK-274 Visibility in 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 86

01/06/2020

Daily Note

Pages: 5

Looking to Establish Strong Roots With REDWOOD-HCM

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 87

11/19/2019

Company Report

Pages: 10

Spotlight on Omecamtiv at AHA Continues to Strengthen Drug''s Profile

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 88

11/01/2019

Company Report

Pages: 7

3Q19 Results; Priorities and Opportunities Are Clear; Upping Price Target to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 89

10/04/2019

Company Report

Pages: 10

ALS Benefit Remains Clear to Us; Path to Phase 3 Seems Evident as We Await Astellas Visibility

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 90

09/16/2019

Company Report

Pages: 12

CK-274 Confirms Desirable Safety and PK/PD Profile; Randomized Phase 2 Insights

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 91

08/09/2019

Company Report

Pages: 7

2Q19 Results; A Thesis to Pay Attention To; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 92

05/10/2019

Company Report

Pages: 7

1Q19 Results; Cardiac Programs in the Spotlight for Now; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 93

05/06/2019

Daily Note

Pages: 4

KOLs Offer Important Perspective About Moving Reldesmtiv Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 94

05/06/2019

Company Report

Pages: 11

Bad Headline, Impressive Data; Reldesemtiv Effects Consistent; Target Increased to $26

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 95

04/23/2019

Company Report

Pages: 7

Data, Drivers, and Decisions; It''s Crunch Time

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 96

03/21/2019

Company Report

Pages: 6

GALACTIC-HF Passes Important Test; Project Visibility on Program to Increase Significantly

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 97

03/19/2019

Company Report

Pages: 9

Omecamtiv Consistently Improves Heart Failure Irrespective of Atrial Fibrillation

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 98

02/22/2019

Company Report

Pages: 8

2018 Results; Ready; Set; Go For Major Catalysts This Year; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 99

01/22/2019

Daily Note

Pages: 4

FDA Appears on Board for SMA Next Steps

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 100

01/22/2019

Company Report

Pages: 8

Multiple Critical Drivers in 2019; the Year of Major Visibility

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party